I do use the word “biotechnology”, but I'm trying to switch over to saying “life sciences” because people can understand it better. You're right: in biotechnology, people think of genetic modification.
There probably is some awareness issue in regard to the general investor, but in regard to what we would consider sophisticated venture capitalists or investors, they're well aware of the life sciences sector. It is a lot like the mining sector with regard to the junior mining sector, because there is a lot of risk.
For people who invest in biotechnology or the life sciences, you have to understand that there's a lot of risk. That's due to a long product development cycle and a lot of risks in development. There are a lot of regulatory hurdles. Just as it is in the mining sector, we have to get a number of different approvals, both in the medical device arena and the therapeutic arena, so it's a very risky investment, as opposed to going into oil and gas or investing in banking or going into a number of things.
I really think the Canadian government has to look at how it can encourage investors to build the agricultural science sector—for example, to develop new seed companies in Canada. I am a proud Canadian, and one of the reasons my partner and I still have the company in Saskatoon is that we have a dream of building a multinational corporation in life science in Saskatoon. We think we have the tools to do it, but I'll tell you that we're fighting every day.
It's as if we're going against the current. When we meet with investment bankers, they continually tell us that it would be easier for us to just be in San Francisco or in the New York, Boston, and New Jersey area.